Skip to content
lifestyle.emphas.is
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Opus Genetics, Inc.
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
July 6, 2026
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
June 26, 2026
Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases
June 16, 2026
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
May 13, 2026
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
May 12, 2026
Opus Genetics Presents Clinical and Preclinical Data at ARVO 2026 Demonstrating Continued Pipeline Advancement in Inherited Retinal Diseases
May 7, 2026
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
May 4, 2026
Opus Genetics to Participate in Leading Medical Conferences in May 2026
April 27, 2026
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
April 6, 2026
1
2
Next Page
→